Evolus, Inc. (EOLS)
$8.88+$0.00 (+0.00%) Today
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
No Form 4 activity for EOLS in the last 90 days.
18 Form 4 filings on record, the earliest from Dec 26, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Rui Avelar - Officer | Open-market sale | Common Stock | 3,119 | $4.75 | $15K | |
| David Moatazedi - Officer | Open-market sale | Common Stock | 13,669 | $4.75 | $65K | |
| David Moatazedi - Officer | Option exercise | Common Stock | 67,489 | $0.00 | - | |
| David Moatazedi - Officer | Open-market sale | Common Stock | 116,720 | $4.89 | $571K | |
| David Moatazedi - Officer | Option exercise | Performance Restricted Stock Units | 67,489 | $0.00 | - | |
| Rui Avelar - Officer | Option exercise | Common Stock | 8,804 | $0.00 | - | |
| Rui Avelar - Officer | Open-market sale | Common Stock | 29,996 | $4.89 | $147K | |
| Rui Avelar - Officer | Option exercise | Performance Restricted Stock Units | 8,804 | $0.00 | - | |
 Karah Herdman Parschauer - Director | Grant or award | Common Stock | 45,559 | $0.00 | - | |
| Brady Stewart - Director | Grant or award | Common Stock | 45,559 | $0.00 | - | |
 Tatjana Mitchell - Officer | Grant or award | Common Stock | 121,489 | $0.00 | - | |
| Tatjana Mitchell - Officer | Grant or award | Performance Restricted Stock Units | 121,489 | $0.00 | - | |
| Tatjana Mitchell - Officer | Grant or award | Stock Option (Right to Buy) | 177,471 | $0.00 | - | |
 Albert G. White III - Director | Grant or award | Common Stock | 45,559 | $0.00 | - | |
| David Moatazedi - Officer | Grant or award | Common Stock | 313,212 | $0.00 | - | |
| David Moatazedi - Officer | Grant or award | Performance Restricted Stock Units | 626,424 | $0.00 | - | |
| David Moatazedi - Officer | Grant or award | Stock Option (Right to Buy) | 457,541 | $0.00 | - | |
 Vikram Malik - Director | Grant or award | Common Stock | 45,559 | $0.00 | - | |
| Rui Avelar - Officer | Grant or award | Common Stock | 94,913 | $0.00 | - | |
| Rui Avelar - Officer | Grant or award | Performance Restricted Stock Units | 94,913 | $0.00 | - | |
| Rui Avelar - Officer | Grant or award | Stock Option (Right to Buy) | 138,649 | $0.00 | - | |
| David N. Gill - Director | Grant or award | Common Stock | 45,559 | $0.00 | - | |
| Tatjana Mitchell - Officer | Grant or award | Common Stock | 104,603 | $0.00 | - | |
| Tatjana Mitchell - Officer | Grant or award | Stock Option (Right to Buy) | 143,403 | $0.00 | - | |
| Tomoko Yamagishi-Dressler - Officer | Open-market sale | Common Stock | 5,722 | $7.51 | $43K | |
| Brady Stewart - Director | Open-market purchase | Common Stock | 30,000 | $6.82 | $204K | |
| David Moatazedi - Officer | Open-market sale | Common Stock | 10,502 | $10.85 | $114K | |
| Rui Avelar - Officer | Open-market sale | Common Stock | 2,252 | $10.85 | $24K | |
| Sandra Beaver - Officer | Open-market sale | Common Stock | 1,586 | $10.85 | $17K |
Evolus, Inc. (EOLS) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-03-20. The full record for EOLS runs to 18 Form 4 filings, the earliest from 2024-12-26. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of EOLS were filed in the last 90 days. 1 purchase is on record for this company.
No insider sales of EOLS were filed in the last 90 days. 8 sales are on record for this company.
This page tracks EOLS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add EOLS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
